A Study of Abatacept in Patients With Active Crohn's Disease

Phase 3 Terminated 451 enrolled Bristol-Myers Squibb

RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn's Disease in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied.

Timeline

Start: 2006-12
Primary completion: 2009-11
Completion: 2009-11

Publications

Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012 Jul;143(1):62-69.e4. doi: 10.1053/j.gastro.2012.04.010. Epub 2012 Apr 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abatacept	Other / unclassified	3 mg/kg	Intravenous
Subject	Abatacept	Other / unclassified	10 mg/kg	Intravenous
Subject	Abatacept	Other / unclassified	30 mg/kg	Intravenous

A Study of Abatacept in Patients With Active Crohn's Disease

Summary

Timeline

Publications

Drugs

Indications